Literature DB >> 9808258

The dopamine D3 receptor antagonist PNU-99194A fails to block (+)-7-OH-DPAT substitution for D-amphetamine or cocaine.

L E Baker1, K A Svensson, K J Garner, A K Goodwin.   

Abstract

The present study examined the role of dopamine D3 receptor actions in the stimulus generalization produced by (+)-7-OH-DPAT in rats trained to discriminate either D-amphetamine or cocaine from saline. Twelve male Sprague-Dawley rats were trained to discriminate D-amphetamine (1.0 mg/kg) and 12 rats were trained to discriminate cocaine (5.0 mg/kg) from saline in a two-choice, water-reinforced operant procedure. Stimulus generalization tests were administered with the D3 receptor-preferring agonist, (+)-7-hydroxy-N, N-di-n-propyl-2-aminotetralin ((+)-7-OH-DPAT, 0.01-1.0 mg/kg) as well as the D3-preferring antagonist, 5,6-di-methoxy-2-(dipropylamino)indan-hydrochloride (PNU-99194A, 5-40 mg/kg). PNU-99194A (10-40 mg/kg) was also administered in combination with the training dose of D-amphetamine or cocaine to test for antagonism of each training drug cue. Finally, to assess the role of D3 receptor actions in the stimulus generalization produced by (+)-7-OH-DPAT (0.1 mg/kg), PNU-99194A (10, 20 mg/kg) was tested in combination with this compound in each training group. The results showed complete stimulus generalization with (+)-7-OH-DPAT in rats trained to discriminate D-amphetamine, although only partial stimulus generalization was observed with this compound in rats trained to discriminate cocaine. PNU-99194A produced partial substitution for both training drugs, and failed to block the discriminative stimulus effects of either D-amphetamine or cocaine. Moreover, this compound failed to block the stimulus generalization produced by (+)-7-OH-DPAT in rats trained to discriminate D-amphetamine. These results question the importance of D3 receptor actions in the discriminative stimulus effects of psychostimulants and their similarities to (+)-7-OH-DPAT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808258     DOI: 10.1016/s0014-2999(98)00582-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

Review 1.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

2.  Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats.

Authors:  Gregory T Collins; Paul Butler; Chris Wayman; Sian Ratcliffe; Paul Gupta; Geoffrey Oberhofer; S Barak Caine
Journal:  Behav Pharmacol       Date:  2012-06       Impact factor: 2.293

3.  Effects of dopamine D(2)-like receptor agonists in mice trained to discriminate cocaine from saline: influence of feeding condition.

Authors:  Gregory T Collins; Jonathan A Jackson; Wouter Koek; Charles P France
Journal:  Eur J Pharmacol       Date:  2014-02-20       Impact factor: 4.432

4.  Levo-tetrahydropalmatine attenuates cocaine self-administration under a progressive-ratio schedule and cocaine discrimination in rats.

Authors:  John R Mantsch; Samantha Wisniewski; Oliver Vranjkovic; Corey Peters; Amanda Becker; Abbey Valentine; Shi-Jiang Li; David A Baker; Zheng Yang
Journal:  Pharmacol Biochem Behav       Date:  2010-09-09       Impact factor: 3.533

5.  Cocaine self-administration in dopamine D₃ receptor knockout mice.

Authors:  S Barak Caine; Morgane Thomsen; Andrew C Barrett; Gregory T Collins; Peter Grundt; Amy Hauck Newman; Paul Butler; Ming Xu
Journal:  Exp Clin Psychopharmacol       Date:  2012-08-06       Impact factor: 3.157

Review 6.  Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations.

Authors:  Sally L Huskinson; Jennifer E Naylor; James K Rowlett; Kevin B Freeman
Journal:  Neuropharmacology       Date:  2014-03-22       Impact factor: 5.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.